Skip Navigation
ChemIDplus A TOXNET DATABASE LiteBrowseAdvanced

Substance Name: Monalizumab [INN]
RN: 1228763-95-8
UNII: 3ZXZ2V0588

Note

  • NCI: anti-NKG2A monoclonal antibody IPH2201 A humanized immunoglobulin G4 (IgG4) monoclonal antibody against the human natural killer (NK) and T-lymphocyte cell checkpoint inhibitor killer cell lectin-like receptor subfamily C member 1 (NKG2A), with potential antineoplastic activity. Upon administration, anti-NKG2A monoclonal antibody IPH2201 binds to NKG2A and prevents the binding of NKG2A to its ligand human leukocyte antigen-E (HLA-E), which is overexpressed on tumor cells. This blocks the HLA-E-mediated inhibition of NKG2A-positive infiltrating NK and cytotoxic T-lymphocytes (CTLs) and induces a NK and CTL-mediated immune response against the cancer cells leading to their destruction. Human NKG2A, an inhibitory cell surface receptor covalently bound to CD94, is expressed by NK cells and CTLs. Stimulation of the CD94/NKG2A complex inhibits the cytotoxic activity of these cells. HLA-E, a nonclassical HLA class Ib molecule, is often overexpressed on tumor cells and is associated with poor prognosis. (NCI Thesaurus)
 
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Other Resources (Internet Locators)

Names and Synonyms

Name of Substance

  • Monalizumab [INN]

Synonyms

  • Immunoglobulin G4-kappa, anti-(homo sapiens KLRC1 (killer cell lectin-like receptor subfamily C member 1, NKG2-a, nkg2a, CD159A, cd94)), humanized monoclonal antibody
  • IPH-2201
  • IPH-2201 (anti-nkg2a)
  • IPH2201
  • Monalizumab
  • Monalizumab [INN]
  • Monalizumab [WHO-DD]
  • NN-8765
  • NN8765
  • NN8765-3658
  • UNII-3ZXZ2V0588

Registry Numbers

CAS Registry Number

  • 1228763-95-8

FDA UNII

  • 3ZXZ2V0588

System Generated Number

  • 1228763958